Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990340 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL7372302 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL13531477 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL23871966 | 0.86 | LMNA (0.61) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL30823376 | 0.86 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL30495884 | 0.85 | LMNA (0.60) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL26840796 | 0.83 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL23662928 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL29486860 | 0.82 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25566258 | 0.82 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | SMN1; SMN2 4221/4885LMNA 3451/4885HTT 4145/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | SMN1; SMN2 4221/4885LMNA 3451/4885HTT 4145/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | SMN1; SMN2 4221/4885LMNA 3451/4885HTT 4145/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | SMN1; SMN2 4221/4885LMNA 3451/4885HTT 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.